Rare, Deadly Complication of Stem Cell Transplants Now Has First Targeted Treatment
Table of Contents
A Christmas Eve FDA decision offers new hope for patients facing a life-threatening side effect of stem cell transplantation.
- The FDA approved narsoplimab (Yartemlea) to treat thrombotic microangiopathy (TA-TMA) associated with stem cell transplants.
- TA-TMA is a severe complication involving blood clot formation in vital organs, often fatal.
- The approval is based on studies showing a 61-68% complete response rate and 73-74% 100-day survival.
- Yartemlea works by inhibiting a key part of the immune system, potentially avoiding interference with infection defense.
A rare but often fatal complication following hematopoietic stem cell transplantation now has its first targeted treatment, offering a critical new option for patients. The Food and Drug Administration approved narsoplimab, marketed as Yartemlea by biotechnology company Omeros, on December 24th, providing a much-needed intervention for adults and children age 2 and older battling thrombotic microangiopathy (TA-TMA) after a stem cell transplant.
Understanding TA-TMA and the Need for New Therapies
TA-TMA is a severe condition characterized by the formation of blood clots in small blood vessels throughout the body, damaging vital organs. Historically, treatment has largely been limited to supportive measures, leaving a significant unmet medical need. Yartemlea represents a paradigm shift, directly addressing the underlying cause of the condition.
How Yartemlea Works: Targeting the Complement System
Omeros specializes in therapies that modulate the complement system, a crucial part of the immune system. Yartemlea is an antibody designed to inhibit MASP-2, a key enzyme within the lectin pathway of the complement system. By blocking MASP-2, the drug aims to prevent the cell injury in small blood vessels driven by this pathway, while carefully avoiding interference with other complement pathways essential for fighting infection.
Clinical Trial Results Demonstrate Efficacy
The FDA’s approval is based on data from a single-arm, open-label study involving 28 adults with TA-TMA, as well as data from an expanded access program including 13 adults and six children. The primary goal of the studies was to demonstrate a complete response, defined as improvement in key laboratory markers of TMA. Researchers also assessed improvements in organ function and transfusion independence.
Results from the TA-TMA study showed a complete response in 17 of 28 adults, or 61%. The expanded access study demonstrated an even higher complete response rate, with 13 of 19 evaluable patients (68%) showing improvement. Importantly, the 100-day survival rate from the time of TMA diagnosis was 73% in the TA-TMA study and 74% in the expanded access study.
Safety Profile and Availability
Omeros reported that all patients in the clinical trials had multiple risk factors for poor outcomes. While adverse reactions were observed, they weren’t directly linked to the study drug. The most common adverse reactions included viral infections, sepsis, hemorrhage, and diarrhea. Notably, Yartemlea’s label does not carry a black box warning, indicating a manageable safety profile.
The company plans to launch Yartemlea in the U.S. in January, with a regulatory decision in Europe anticipated in mid-2026. Omeros has scheduled a conference call for Monday, December 29, to discuss the approval in detail.
Other Recent FDA Approvals
New Therapies for Heart and Lung Conditions
The FDA has also recently approved several new treatments for cardiovascular and pulmonary diseases. Novo Nordisk’s Wegovy pill, the first oral GLP-1 drug for weight loss, also received approval for reducing the risk of major cardiovascular events like heart attack and stroke.
Cytokinetics’s Myqorvo was approved as a treatment for obstructive hypertrophic cardiomyopathy (oHCM), offering more flexible safety and monitoring requirements compared to a competing drug. GSK’s Exdensur, a new biologic medicine for severe asthma, provides less frequent dosing—administered as an injection twice a year—compared to existing treatments.
Milestone Pharmaceuticals’ Cardamyst, a nasal spray formulation for paroxysmal supraventricular tachycardia (PSVT), offers a rapid-acting treatment option.
Advances in Rare Disease Treatment
Agios’s Aqvesme (mitapivat) is now the sole FDA-approved treatment for non-transfusion dependent and transfusion-dependent alpha- or beta thalassemia. Waskyra marks the first gene therapy for Wiskott-Aldrich syndrome, and the first FDA approval for a non-profit applicant.
Arrowhead Pharmaceuticals’ Redemplo received approval for familial chylomicronemia syndrome (FCS), while Novartis’s Zolgensma expanded its approval to patients age 2 and older under the brand name Itvisma. Otsuka’s Voyxact gained accelerated approval for immunoglobulin A nephropathy (IgAN), and BioCryst’s Orladeyo now has an oral pellet formulation for hereditary angioedema.
Cancer Treatment Updates
Darzalex Faspro received traditional FDA approval for newly diagnosed light chain amyloidosis, and Amgen’s Uplizna expanded its approved uses to include generalized myasthenia gravis. Gamida Cell’s Omisirge was approved for severe aplastic anemia, offering an option for patients without a matched donor.
UCB’s Kygevi became the first FDA-approved treatment for thymidine kinase 2 deficiency. Enhertu, from AstraZeneca and Daiichi Sankyo, is now approved for first-line treatment of HER2-positive metastatic breast cancer. Johnson & Johnson’s Rybrevant now has a subcutaneous injection option, and Merck’s Keytruda received marketing authorization in Europe in a subcutaneous form.
Amgen’s Imdelltra converted its accelerated approval to full FDA approval for extensive-stage small cell lung cancer. Bayer’s Hyrnuo won FDA approval for advanced HER2-mutated non-small cell lung cancer, and AstraZeneca’s Imfinzi expanded its label to include perioperative therapy for early gastric and gastroesophageal cancers.
Johnson & Johnson’s Akeega added metastatic castration-resistant prostate cancer to its label, and Kura Oncology’s Komzifti landed FDA approval for acute myeloid leukemia. Syndax’s Revuforj expanded its label to include relapsed or refractory acute myeloid leukemia. Pfizer’s Padcev expanded its approval to include perioperative use for muscle-invasive bladder cancer, and AbbVie’s Epkinly is now approved for relapsed or refractory follicular lymphoma.
Eli Lilly’s pirtobrutinib, brand name Jaypirca, converted its accelerated approval to full FDA approval for chronic lymphocytic leukemia and small lymphocytic lymphoma.
Recent Infectious Disease Approvals
The FDA recently approved two new oral gonorrhea treatments: GSK’s Blujepa and Inoviva Specialty Therapeutics’ Nuzolvence.
Regulatory Setbacks
The FDA turned down Sanofi’s application for tolebrutinib as a treatment for non-relapsing secondary progressive multiple sclerosis, requesting further guidance.
